Bank of America flags international opportunities as key growth driver for Moderna

$950 million upfront payment in Q1 materially reduces Moderna's litigation overhang, though up to $1.3 billion in additional payments could still be triggered depending on an ongoing legal appeal. Bank of America expects Moderna to emphasize progress in international COVID-19 vaccine markets when reporting Q1 2026 as the 2025-2026 vaccine season winds down. Monitor management commentary for updates to litigation exposure and international demand, which will influence near-term cash flow and guidance.

Analysis

The near-term picture is about de-risking and reallocation rather than a demand shock: with legal and seasonal noise receding, management choices (buybacks, M&A, or reinvesting in global commercial footprint) will disproportionately determine earnings momentum over the next 6–18 months. If management shifts incremental dollars from one‑time remediation toward recurring commercial build-out in underpenetrated international markets, expect operating leverage to flow through to margins as fixed manufacturing and SG&A are absorbed — a 10–20% improvement in gross margin is plausible on a durable +20–30% higher baseline utilization over 12–24 months.

Second-order winners are suppliers and service providers that can flex capacity quickly: fill/finish CDMOs and ionizable‑lipid/material suppliers stand to capture outsized margin expansion as volumes normalize and pricing shifts from spot to contract. Conversely, low‑cost protein or adjuvanted vaccine entrants will exert downward pricing pressure in price‑sensitive markets, pressuring ASPs and forcing trade promotion spending that can shave several hundred basis points off gross margins in exposed geographies over a 1–2 year window.

Key catalysts to watch by horizon: days — earnings cadence and guidance resets that reprice ramp expectations; months — legal/appeal outcomes and any announced capital return programs that change free‑cash‑flow deployment; 12–36 months — competitive efficacy/readout and procurement decisions by large public health buyers. A single regulatory reversal or a surprise efficacy miss against a new variant remains the clearest path to a >30% equity reset, while successful conversion of seasonal demand into a repeatable booster business is the central bull case that could re-rate multiples by 20–40%.

Key Decisions for Investors

• Directional call-spread on MRNA (6–12 month tenor): enter a debit call spread sized 1–2% NAV (long ~30% OTM call / short ~80% OTM call). Rationale: asymmetric upside if management redeploys capital toward durable revenue channels; limited max loss = premium. Exit: roll or take profits at 2.5x premium or on signs of sustained ASP erosion.
• Paired equity trade (6–18 months): long MRNA (1% NAV) / short BNTX (1% NAV) — dollar‑neutral. Rationale: plays capture of international commercialization execution while hedging macro vaccine demand risk. Trim if relative share wins narrow to <5% or if both names show synchronized safety/regulatory headlines.
• Volatility‑aware hedge ahead of earnings (days): buy a cheap put‑spread on MRNA (30–90 day, 20–30% OTM) to cap downside on any post‑earnings drawdown while avoiding full IV decay cost. Target cost <0.5% NAV for protection against a >20% gap down.
• Supply‑chain long (12–24 months): selectively increase exposure to proven fill/finish CDMOs (e.g., CTLT or LON) by 1–2% NAV to capture higher contracted volumes and pricing resilience. Risk: demand re-pricing to low-cost suppliers; take profits on 20–30% move higher or if utilization signals reverse.